Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: KeepItSimple who wrote (163374)	5/4/2002 12:21:56 AM
From: EepOpp	Read Replies (1) \| Respond to of 436258

Arthritis drug 'could treat spine condition' news.bbc.co.uk ____________________ Friday, 3 May, 2002, 23:08 GMT 00:08 UK Arthritis drug 'could treat spine condition' Mike Atherton has been a high-profile sufferer A crippling spinal condition could be treated with a drug normally used to help people with rheumatoid arthritis, researchers suggest. US scientists say the drug etanercept can significantly relieve ankylosing spondylitis (AS). In the study, it relieved symptoms in four-fifths of patients. AS is a heredity back condition which causes progressive stiffening of the spine, and which, if left untreated, can cripple sufferers. ______________________ This is an excellent study, and it's great news for AS patients Dr Madeleine Devey, Arthritis Research Campaign ______________________ Other joints such as the hips, shoulders, knees, or ankles can also be affected. There is currently no cure for the condition. Every year, an estimated 200,000 visit their GP with AS. Former England cricketer Mike Atherton is one of the most high-profile sufferers. His father was also affected. Etanercept was recently approved for NHS use for patients with severe rheumatoid arthritis. The US research showed it worked faster than the current therapies such as aspirin-like drugs, other immunosuppressives and physical therapy in treating AS. The drug may reduce spinal inflammation and actually slow the progress of the disease, the researchers suggest. Inflammation control AS, like rheumatoid arthritis, is an autoimmune disease in which the immune system can no longer control proteins called cytokines. These attack the body, prompting a damaging increase in inflammation. Etanercept is a Tumour Necrosis Factor alpha blocker (anti-TNF). It works by switching off TNF, which stimulates cells to produce that inflammation response. In the study, carried out by researchers from the University of California - San Francisco 20 patients were given the drug and 20 more a dummy version. Of those who were given etanercept, 80% said they had less stiffness, less pain and improved functioning. Only 30% of those in the other group showed such improvements. The benefits of etanercept lasted for the duration of the study, and though there were side effects, they were mild. A larger study is now underway. In April, German researchers found another drug used to treat rheumatoid arthritis, infliximab, showed similarly promising results in the treatment of AS. Access query Jennifer Gorman, assistant adjunct professor of medicine at UCSF, who led the US study said: "Both these results are very encouraging for patients with spondylitis. "The development of anti-tumour necrosis factor therapies has finally given us the opportunity to effectively treat some of the most disabling symptoms in this disease." Dr Madeleine Devey, scientific officer for the Arthritis Research Campaign, told BBC News Online: "This is an excellent study, and it's great news for AS patients. "Use of TNF blockers in rheumatoid arthritis has recently been approved by the National Institute of Clinical Excellence in the UK but it is very likely that their use in AS will have to undergo a separate assessment so it is not clear whether AS patients will have access to the therapy in the UK except as part of a clinical trial." The research is published in the New England Journal of Medicine.